Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.5
Journals
Cancers
Special Issues
Genetic Analysis and Clinical Therapy in Head and Neck Cancers
share announcement

Genetic Analysis and Clinical Therapy in Head and Neck Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 30 July 2025 | Viewed by 2391

Special Issue Editor

Dr. Alfonso Scarpa

E-Mail Website
Guest Editor
Department of Otolaryngology, University Hospital, “San Giovanni di Dio e Ruggi d’Aragona”, 84131 Salerno, Italy
Interests: tumor immunology; molecular pathogenesis; microcirculation; machine learning; salivary gland disorders; cancer diagnostics; cancer stem cells; regenerative medicine

Special Issue Information

Dear Colleagues,

This Special Issue, “Genetic Analysis and Clinical Therapy in Head and Neck Cancers”, aims to provide a comprehensive platform for researchers and clinicians to explore the intricate relationship between genetic factors and clinical therapeutic approaches in the context of head and neck cancers. As advances in genomic research continue to unravel the complexities of cancer biology, understanding the genetic underpinnings of head and neck cancers has become crucial for developing targeted and personalized treatment strategies. This Special Issue invites contributions that bridge the gap between genetic insights and clinical applications, fostering a deeper understanding of the molecular mechanisms driving these cancers and facilitating the translation of genetic knowledge into effective therapeutic interventions. Join us in advancing the frontiers of knowledge in head and neck cancer research, with a focus on integrating genetic analysis into clinical practice.

Dr. Alfonso Scarpa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • head and neck cancers
  • genetic analysis
  • clinical therapy
  • personalized treatment
  • molecular mechanisms
  • cancer biology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 2276 KiB  
Article
WBP5 Expression Influences Prognosis and Treatment Response in Head and Neck Squamous Cell Carcinoma
by Eun-jeong Jeong, Eunjeong Kim, Kwang-Yoon Jung, Seung-Kuk Baek and Yeon Soo Kim
Cancers 2025, 17(4), 587; https://doi.org/10.3390/cancers17040587 - 8 Feb 2025
Viewed by 946
Abstract
Objectives: Head and neck squamous cell carcinoma (HNSCC) is characterized by complex genetic alterations. This study aimed to identify WBP5 as a promising therapeutic target and evaluate the effect of WBP5 expression on prognosis and treatment response in HNSCC. Methods: Publicly available datasets [...] Read more.
Objectives: Head and neck squamous cell carcinoma (HNSCC) is characterized by complex genetic alterations. This study aimed to identify WBP5 as a promising therapeutic target and evaluate the effect of WBP5 expression on prognosis and treatment response in HNSCC. Methods: Publicly available datasets were comprehensively analyzed to investigate WBP5 expression through comprehensive bioinformatics analysis and functional validation. Results: WBP5 was particularly overexpressed in HNSCC, as analyzed through the Gene Expression Profiling Interactive Analysis version 2 (GEPIA2) database and validated using multiple Gene Expression Omnibus (GEO) datasets. Analysis with UALCAN confirmed that WBP5 expression was significantly higher in advanced cancer stages and tumor grades than that of normal samples. A Kaplan–Meier analysis demonstrated that patients overexpressing WBP5 had a poor prognosis. Moreover, WBP5 expression correlated with the overexpression of the epidermal growth factor receptor in HNSCC. In vitro experiments revealed that WBP5 knockdown significantly reduced FaDu cell proliferation and viability. Furthermore, silencing WBP5 enhanced cisplatin sensitivity, indicating its potential role in chemoresistance. Conclusions: These results indicate that WBP5 could act as a prognostic marker and a viable therapeutic target in HNSCC. Modulating WBP5 expression may represent a novel strategy to enhance treatment efficacy. Future studies should elucidate the precise mechanisms of WBP5 action and develop targeted therapies. This integrated approach, combining a comprehensive analysis of publicly available datasets with in vitro experimental validation provides strong evidence for the clinical significance of WBP5 in HNSCC. Full article
(This article belongs to the Special Issue Genetic Analysis and Clinical Therapy in Head and Neck Cancers)
►▼ Show Figures

Figure 1

14 pages, 3967 KiB  
Article
Clinical Introduction of Stem Cell Sparing Radiotherapy to Reduce the Risk of Xerostomia in Patients with Head and Neck Cancer
by Maria I. van Rijn-Dekker, Arjen van der Schaaf, Sanne W. Nienhuis, Antoinette S. Arents-Huls, Rachel B. Ger, Olga Hamming-Vrieze, Frank J. P. Hoebers, Mischa de Ridder, Sabrina Vigorito, Ellen M. Zwijnenburg, Johannes A. Langendijk, Peter van Luijk and Roel J. H. M. Steenbakkers
Cancers 2024, 16(24), 4283; https://doi.org/10.3390/cancers16244283 - 23 Dec 2024
Viewed by 976
Abstract
Background/Objectives: Studies have shown that dose to the parotid gland stem cell rich (SCR) regions should be reduced to lower the risk of xerostomia after radiotherapy (RT). This study aimed to assess whether stem cell sparing (SCS)-RT can be adopted in routine clinical [...] Read more.
Background/Objectives: Studies have shown that dose to the parotid gland stem cell rich (SCR) regions should be reduced to lower the risk of xerostomia after radiotherapy (RT). This study aimed to assess whether stem cell sparing (SCS)-RT can be adopted in routine clinical practice. Methods: Multiple planning studies were performed to compare SCS-RT with standard (ST)-RT using 30 head and neck cancer patients. Shifts in mean dose to the SCR regions (Dmean,SCR) and other organs at risk and their estimated impact on normal tissue complication probability (NTCP) for side-effects were compared using Wilcoxon signed-rank test. A multicenter study was performed (eight institutions, three patients) to test the generalizability of SCS-RT using the Friedman test. Results: Using photons, Dmean,SCR was reduced with median 4.1/3.5 Gy for ipsilateral/contralateral (p < 0.001). The largest reductions were when the SCR regions overlapped less with target volumes. Subsequently, NTCPs for xerostomia decreased (p < 0.001). Using protons, Dmean,SCR was also reduced (2.2/1.9 Gy for ipsilateral/contralateral, p < 0.002). Nevertheless, SCS-RT did not further decrease NTCPs for xerostomia (p > 0.17). Target coverage and prevention of other side-effects were not compromised. However, increased mean oral cavity dose was observed in some patients. Lastly, in the multicenter study Dmean,SCR could be reduced by slightly adjusting the standard optimization. Contralateral Dmean,SCR reductions differed between centers (p = 0.01), which was attributed to differences in ST-RT plans. Conclusions: Stem cell sparing radiotherapy can be clinically introduced by making small adjustments to the optimization strategy and can reduce the risk of xerostomia. Full article
(This article belongs to the Special Issue Genetic Analysis and Clinical Therapy in Head and Neck Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop